Dorsey & Whitney Trust CO LLC Has $640,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Dorsey & Whitney Trust CO LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 13.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 3,927 shares of the company’s stock after selling 594 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Zoetis were worth $640,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in ZTS. Howard Capital Management Group LLC lifted its position in shares of Zoetis by 0.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after purchasing an additional 883 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Zoetis by 17.3% during the 3rd quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after purchasing an additional 351,372 shares during the last quarter. Summit Global Investments lifted its position in shares of Zoetis by 344.8% during the 3rd quarter. Summit Global Investments now owns 5,173 shares of the company’s stock worth $1,011,000 after purchasing an additional 4,010 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in Zoetis in the 3rd quarter valued at approximately $33,000. Finally, CWA Asset Management Group LLC acquired a new position in Zoetis in the 3rd quarter valued at approximately $1,431,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent research reports. Leerink Partners initiated coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Barclays upped their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday. Finally, Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus price target of $215.90.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Zoetis Trading Up 1.8 %

Shares of ZTS opened at $170.34 on Monday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a 50 day simple moving average of $166.72 and a 200-day simple moving average of $176.74. The stock has a market cap of $76.28 billion, a PE ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. Zoetis’s dividend payout ratio is 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.